Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Free Cash Flow (2016 - 2025)

IGC Pharma (IGC) has disclosed Free Cash Flow for 16 consecutive years, with -$2.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow fell 106.73% to -$2.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$5.6 million, a 12.27% decrease, with the full-year FY2025 number at -$4.9 million, up 8.06% from a year prior.
  • Free Cash Flow was -$2.1 million for Q3 2025 at IGC Pharma, down from -$1.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$541000.0 in Q1 2024 to a low of -$2.6 million in Q1 2021.
  • A 5-year average of -$1.7 million and a median of -$1.7 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: soared 64.45% in 2024, then crashed 106.73% in 2025.
  • IGC Pharma's Free Cash Flow stood at -$2.4 million in 2021, then rose by 8.94% to -$2.2 million in 2022, then increased by 25.78% to -$1.7 million in 2023, then rose by 18.79% to -$1.3 million in 2024, then crashed by 57.66% to -$2.1 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Free Cash Flow are -$2.1 million (Q3 2025), -$1.4 million (Q2 2025), and -$748000.0 (Q1 2025).